<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04347122</url>
  </required_header>
  <id_info>
    <org_study_id>00144738</org_study_id>
    <nct_id>NCT04347122</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction</brief_title>
  <official_title>Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to determine if any correlation exists between administration of TXA or&#xD;
      not to musculoskeletal oncology patients undergoing endoprosthetic reconstruction and blood&#xD;
      loss and blood transfusion rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Resection of bony and soft tissue tumors with endoprosthetic reconstruction often presents a&#xD;
      significant risk of perioperative blood loss requiring transfusion. Tranexamic acid (TXA) is&#xD;
      an antifibrinolytic that is commonly used to reduce blood loss in orthopedic procedures, most&#xD;
      often arthroplasty. The aim of this study is to determine in a randomized controlled fashion&#xD;
      if there is any difference in perioperative blood loss and blood transfusion rates when TXA&#xD;
      is used compared to when it is not used in patients undergoing radical resection of bone and&#xD;
      soft tissue sarcomas with endoprosthetic reconstruction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are randomized to one of four groups. One group is the bony tumor treated with TXA, second group is the bony tumor treated without TXA, third group is the soft tissue sarcoma treated with TXA, and the fourth group is soft tissue sarcoma treated without TXA.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative blood loss</measure>
    <time_frame>Postoperative days 1-3</time_frame>
    <description>Perioperative blood loss measured by the hemoglobin balance method at postoperative days 1-3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion rates</measure>
    <time_frame>Postoperative days 1-3</time_frame>
    <description>Number of required blood transfusions up to 3 days following surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical drain output</measure>
    <time_frame>Postoperative days 1-3</time_frame>
    <description>Surgical drain output as measured in ml for 3 days following surgery</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Musculoskeletal Cancer</condition>
  <condition>Sarcoma,Soft Tissue</condition>
  <arm_group>
    <arm_group_label>Bony tumor treated with Tranexamic acid (TXA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of participants will undergo a bony tumor resection of the femur or proximal tibia and endoprosthetic reconstruction with TXA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bony tumor treated without TXA</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group of participants will undergo a bony tumor resection of the femur of proximal tibia and endoprosthetic reconstruction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soft tissue sarcoma treated with Tranexamic Acid (TXA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of participants will undergo soft tissue sarcoma resection of the lower extremity with TXA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soft tissue sarcoma treated without TXA</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group of participants will undergo soft tissue sarcoma resection of the lower extremity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid (TXA)</intervention_name>
    <description>Intervention groups will receive TXA 1g TXA IVPB 10 minutes prior to incision and a second dose of 1g IVPB at the time of closure.</description>
    <arm_group_label>Bony tumor treated with Tranexamic acid (TXA)</arm_group_label>
    <arm_group_label>Soft tissue sarcoma treated with Tranexamic Acid (TXA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing wide resection of a malignant bony tumor of the lower extremity&#xD;
             with endoprosthetic reconstruction.&#xD;
&#xD;
          -  Patients undergoing a resection of soft tissue sarcoma measuring &gt; 5cm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing revision endoprosthetic reconstruction&#xD;
&#xD;
          -  Patients with known coagulopathy&#xD;
&#xD;
          -  Known history of DVT or embolic disease&#xD;
&#xD;
          -  Benign tumors&#xD;
&#xD;
          -  Patients with allergy to TXA&#xD;
&#xD;
          -  Those refusing blood products&#xD;
&#xD;
          -  Those concurrently on anti-coagulant therapy&#xD;
&#xD;
          -  Pregnant and/or nursing women&#xD;
&#xD;
          -  Vulnerable populations as defined by the KUMC IRB&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyle Sweeney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>S Bradshaw</last_name>
    <phone>913-945-6289</phone>
    <email>sbradshaw2@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S Bradshaw</last_name>
      <phone>913-945-6289</phone>
      <email>sbradshaw2@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>K Sweeney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Kyle Sweeney, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

